Transcenta Holding Future Growth
Future criteria checks 2/6
Transcenta Holding is forecast to grow earnings and revenue by 12.7% and 67.8% per annum respectively while EPS is expected to grow by 12.6% per annum.
Key information
12.7%
Earnings growth rate
12.6%
EPS growth rate
| Biotechs earnings growth | 42.9% |
| Revenue growth rate | 67.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 03 Sep 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 339 | -265 | -86 | 85 | 1 |
| 12/31/2025 | 138 | -366 | -408 | -265 | 2 |
| 12/31/2024 | 132 | -421 | -1,026 | -565 | 1 |
| 6/30/2024 | 22 | -359 | -282 | -280 | N/A |
| 3/31/2024 | 38 | -411 | -328 | -319 | N/A |
| 12/31/2023 | 54 | -463 | -374 | -358 | N/A |
| 9/30/2023 | 85 | -451 | -364 | -343 | N/A |
| 6/30/2023 | 116 | -440 | -355 | -329 | N/A |
| 3/31/2023 | 109 | -424 | -336 | -312 | N/A |
| 12/31/2022 | 102 | -407 | -318 | -296 | N/A |
| 9/30/2022 | 74 | -666 | -371 | -337 | N/A |
| 6/30/2022 | 45 | -925 | -424 | -377 | N/A |
| 3/31/2022 | 53 | -1,748 | -467 | -419 | N/A |
| 12/31/2021 | 50 | -1,716 | -440 | -384 | N/A |
| 9/30/2021 | 65 | -1,457 | -377 | -321 | N/A |
| 6/30/2021 | 79 | -1,199 | -314 | -258 | N/A |
| 3/31/2021 | 82 | -364 | -256 | -180 | N/A |
| 12/31/2020 | 81 | -317 | -238 | -174 | N/A |
| 12/31/2019 | 44 | -395 | -457 | -235 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6628 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6628 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6628 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6628's revenue (67.8% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 6628's revenue (67.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6628's Return on Equity is forecast to be high in 3 years time